Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :30272276
Publication Date : //

Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87.


Glioblastoma is the most common and lethal intracranial tumor type, characterized by high angiogenic and infiltrative capacities. To provide a novel insight into therapeutic strategies against glioblastoma, the cytotoxicity of arenobufagin and hellebrigenin was investigated in the human glioblastoma cell line, U-87. Similar dose-dependent cytotoxicity was observed in the cells, whereas no detectable toxicity was confirmed in mouse primary astrocytes. Treatment with each drug downregulated the expression levels of Cdc25C, Cyclin B1 and survivin, which occurred in parallel with G2/M phase arrest. Necrotic-like cell death was only observed in the cells treated with a relatively high concentration (>100 ng/ml). These results indicate that the two drugs exhibited distinct cytotoxicity against cancerous glial cells with high potency and selectivity, suggesting that growth inhibition associated with G2/M phase arrest and/or necrosis were attributed to their toxicities. Activation of the p38 mitogen activated protein kinase (MAPK) signaling pathway was also observed in treated cells. Notably, a specific inhibitor of p38 MAPK, SB203580, itself caused a significant decrease in cell viability, and further enhanced the cytotoxicity of the two drugs, suggesting an important pro-survival role for p38 MAPK. Given that p38 MAPK serves an essential role in promoting glioblastoma cell survival, developing a novel combination regimen of arenobufagin/hellebrigenin plus a p38 MAPK inhibitor may improve the efficacy of the two drugs, and may provide more therapeutic benefits to patients with glioblastoma. The qualitative assessment demonstrated the existence of arenobufagin in the cerebrospinal fluid of arenobufagin-treated rats, supporting its clinical application.

Authors : Han Lingyu , Yuan Bo , Shimada Ryota , Hayashi Hideki , Si Nan , Zhao Hai-Yu , Bian Baolin , Takagi Norio ,

Related products :

Catalog number Product name Quantity
LF-R0008 U87MG Cell Lysate (Human glioblastoma cell line) 200 ul
SC605A-GBM Stem Cell Products Human Glioblastoma multiforme iPS Cell Line (Academic customers) 2x10^5 cells
SC605B-GBM Stem Cell Products Human Glioblastoma multiforme iPS Cell Line (Commercial customers) 2x10^5 cells
SC605A-GBM Human Glioblastoma multiforme iPS Cell Line (Academic customers) 2x10^5 cells
SC605B-GBM Human Glioblastoma multiforme iPS Cell Line (Commercial customers) 2x10^5 cells
30-204 Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are med 0.1 mg
SC018-Neo Color Switch, CRE report cell line: HEK293-loxP-GFP-RFP Neo) : CRE reporter cell line (Neo): HEK293 cell line expressing "LoxP-GFP-stop-LoxP-RFP" cassette with Neomycin antibiotic marker 2x10E6 cell/ml x1ml
SC018-Bsd Color Switch, CRE report cell line: HEK293-loxP-GFP-RFP (Bsd) : CRE reporter cell line (Bsd): HEK293 cell line expressing "LoxP-GFP-stop-LoxP-RFP" cassette with Blasticidin antibiotic marker 2x10E6 cell/ml x1ml
CL1032 293T Cell Line Subtitle Human Cell Line T-25 flask
CL1001 Hela Cell Line Subtitle Human Cell Line T-25 flask
CL1033 A549 Cell Line Subtitle Human Cell Line T-25 flask
CL1025 NCI-H292 Cell Line Subtitle Human Cell Line T-25 flask
CL1031 U251 Cell Line Subtitle Human Cell Line T-25 flask
CL1007 Jurkat Cell Line Subtitle Human Cell Line T-25 flask
CL1009 NCI-H460 Cell Line Subtitle Human Cell Line T-25 flask
CL1027 WiDr Cell Line Subtitle Human Cell Line T-25 flask
CL1005 T47D Cell Line Subtitle Human Cell Line T-25 flask
CL1006 A375 Cell Line Subtitle Human Cell Line T-25 flask
CL1030 SiHa Cell Line Subtitle Human Cell Line T-25 flask
CL1012 Ramos Cell Line Subtitle Human Cell Line T-25 flask
CL1013 HL60 Cell Line Subtitle Human Cell Line T-25 flask
CL1008 A2058 Cell Line Subtitle Human Cell Line T-25 flask
CL1011 HepG2 Cell Line Subtitle Human Cell Line T-25 flask
CL1010 K562 Cell Line Subtitle Human Cell Line T-25 flask
CL1015 174 CEM Cell Line Subtitle Human Cell Line T-25 flask


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur